Compare ITG & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITG | PRME |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.3M | 526.0M |
| IPO Year | 2026 | 2022 |
| Metric | ITG | PRME |
|---|---|---|
| Price | $5.00 | $3.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $14.56 | $7.11 |
| AVG Volume (30 Days) | 715.7K | ★ 4.5M |
| Earning Date | 11-10-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $35.08 | $90.65 |
| Revenue Next Year | $20.34 | $19.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $4.60 | $2.67 |
| 52 Week High | $16.00 | $5.10 |
| Indicator | ITG | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 26.39 | 52.12 |
| Support Level | N/A | $2.89 |
| Resistance Level | $14.15 | $3.64 |
| Average True Range (ATR) | 0.71 | 0.36 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 8.58 | 50.68 |
ITG Inc provides services to the digital and other utility infrastructure industries throughout the United States. Its services support the planning, design, construction, operation, maintenance, and expansion of broadband and other infrastructure networks. It operates through two complementary service lines: i) Engineering & Maintenance: It provides re-occurring, mission-critical services required by network owners to operate, maintain, optimize and expand their infrastructure. ii) Infrastructure Deployment. It provides large-scale network and fiber construction services for incumbent carriers, overbuilders, and data center operators and underground civil construction services for public and private utilities. The majority of revenue is derived from the Engineering & Maintenance services.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.